



14 December 2020

Dear Optionholder

CYNATA THERAPEUTICS 1 FOR 15 PRO RATA NON-RENOUNCEABLE ENTITLEMENT OFFER – LETTER TO OPTIONHOLDERS

On 11 December 2020, Cynata Therapeutics Limited (the **Company** or **CYP**) announced that it will be undertaking a non-renounceable, non-accelerated pro rata entitlement offer (**Rights Issue**) of up to approximately 7,807,267 fully paid ordinary shares in the Company (**New Shares**) at an issue price of \$0.70 per New Share (**Offer Price**) to raise up to approximately \$5.47 million.

The Rights Issue is not underwritten.

The Rights Issue is being conducted in conjunction with a placement of New Shares to professional and sophisticated investors at the Offer Price (**Placement**). The Placement will raise approximately \$15 million. The New Shares issued under the Placement will not be entitled to participate in the Rights Issue.

The Rights Issue will entitle eligible shareholders with a registered address in Australia and New Zealand (**Eligible Shareholders**) to subscribe for 1 New Share for every 15 ordinary shares held in the Company as at the record date of 7.00pm (Melbourne time) on 16 December 2020 (**Record Date**).

Action required by Optionholders who wish to participate in the Rights Issue

The purpose of this letter is to give you notice that if you wish to participate in the Rights Issue with respect to your options, you must exercise and pay for your options before the Record Date of 7:00pm (Melbourne time) on 16 December 2020.

To ensure that your shares are allotted before the Record Date, your option exercise notice together with the correct monies must be received by the Company's Share Registry, Automic Pty Ltd, no later than 5:00pm (Melbourne time) on 15 December 2020. Any notice of exercise of options received after this date cannot be assured of allotment before the Record Date.

If you do not wish to participate in the Rights Issue in respect of your options, you do not need to take any action.

Before deciding whether to exercise all or any of your options, you should consider the terms of the Rights Issue carefully and if in any doubt, consult with your professional advisor.

Eligible Shareholders

The Company is making the Rights Issue available to Eligible Shareholders only. Eligible Shareholders are persons who:

- are registered as shareholders of the Company on the Record Date;
- have a registered address in Australia or New Zealand, or are otherwise determined by the Company to be eligible to participate in the Rights Issue;
- are not ineligible to participate in the Offer;
- are not in the United States and are not acting for the account or benefit of a person in the United States (to the extent such person holds Shares for the account or benefit of such person in the United States); and
- are eligible under all applicable securities laws to receive and participate in the Rights Issue.

Offer Period

The Rights Issue will be open for acceptance by Eligible Shareholders from 21 December 2020 to 13 January 2021, subject to variation of the timetable by the Company in accordance with the ASX Listing Rules and the Corporations Act. Any changes to the timetable will be announced on the ASX.


Entitlement Offer Booklet

Full details of the Rights Issue, together with a personalised entitlement and acceptance form, will be set out in an information booklet, copies of which will be despatched to Eligible Shareholders and available on the ASX website (www.asx.com.au) from 21 October 2020. Eligible Shareholders should also have regard to the investor presentation and ASX announcement lodged with ASX on 11 December 2020 and available on the ASX website.

Further information

If you require any further information please contact the Company's Share Registry, Automic Pty Ltd, on 1300 288 664. You may also wish to contact your stockbroker, solicitor, accountant or other professional advisor.

Authorised by



Peter Webse
Company Secretary

Contacts: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343,
ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, + 315.765.1462,
clacagnina@6degreespr.com